Literature DB >> 11569781

Does complete resection of melanoma metastatic to solid intra-abdominal organs improve survival?

T F Wood1, L A DiFronzo, D M Rose, P I Haigh, S L Stern, L Wanek, R Essner, D L Morton.   

Abstract

BACKGROUND: Patients with distant melanoma metastases have median survivals of 4 to 8 months. Previous studies have demonstrated improved survival after complete resection of pulmonary and hollow viscus gastrointestinal metastases. We hypothesized that patients with metastatic disease to intra-abdominal solid organs might also benefit from complete surgical resection.
METHODS: A prospectively acquired database identified patients treated for melanoma metastatic to the liver, pancreas, spleen, adrenal glands, or a combination of these from 1971 to 2000. The primary intervention was complete or incomplete surgical resection of intra-abdominal solid-organ metastases, and the main outcome measure was postoperative overall survival (OS). Disease-free survival (DFS) was a secondary outcome measure.
RESULTS: Sixty patients underwent adrenalectomy, hepatectomy, splenectomy, or pancreatectomy. Median OS was significantly improved after complete versus incomplete resections, but median OS after complete resection was not significantly different for single-site versus synchronous multisite metastases. The 5-year survival in the group after complete resection was 24%, whereas in the incomplete resection group, there were no 5-year survivors. Median DFS after complete resection was 15 months. Of note, the 2-year DFS after complete resection was 53% for synchronous multi-site metastases versus 26% for single-site metastases.
CONCLUSIONS: In highly selected patients with melanoma metastatic to intra-abdominal solid organs, aggressive attempts at complete surgical resection may improve OS. It is important that the number of metastatic sites does not seem to affect the OS after complete resection.

Entities:  

Mesh:

Year:  2001        PMID: 11569781     DOI: 10.1007/s10434-001-0658-4

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  40 in total

1.  Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I).

Authors:  J Harrison Howard; John F Thompson; Nicola Mozzillo; Omgo E Nieweg; Harald J Hoekstra; Daniel F Roses; Vernon K Sondak; Douglas S Reintgen; Mohammed Kashani-Sabet; Constantine P Karakousis; Brendon J Coventry; William G Kraybill; B Mark Smithers; Robert Elashoff; Stacey L Stern; Alistair J Cochran; Mark B Faries; Donald L Morton
Journal:  Ann Surg Oncol       Date:  2012-05-31       Impact factor: 5.344

2.  Direct comparison of [18F]FDG PET/CT with PET alone and with side-by-side PET and CT in patients with malignant melanoma.

Authors:  Felix M Mottaghy; Cord Sunderkötter; Roland Schubert; Petra Wohlfart; Norbert M Blumstein; Bernd Neumaier; Gerhard Glatting; Cueneyt Ozdemir; Andreas K Buck; Karin Scharffetter-Kochanek; Sven N Reske
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-02-13       Impact factor: 9.236

3.  Two cases of partial hepatectomy for malignant melanoma.

Authors:  Aaron I Karlen; Justin J Clark; Linda L Wong
Journal:  Hawaii J Med Public Health       Date:  2012-04

4.  Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome.

Authors:  Joseph Kim; Takuji Mori; Steven L Chen; Farin F Amersi; Steve R Martinez; Christine Kuo; Roderick R Turner; Xing Ye; Anton J Bilchik; Donald L Morton; Dave S B Hoon
Journal:  Ann Surg       Date:  2006-07       Impact factor: 12.969

Review 5.  Surgery and sentinel lymph node biopsy.

Authors:  Mark B Faries; Donald L Morton
Journal:  Semin Oncol       Date:  2007-12       Impact factor: 4.929

Review 6.  Pancreatic resection for metastatic melanoma. Case report and review of the literature.

Authors:  Cosimo Sperti; Maria Laura Polizzi; Valentina Beltrame; Margherita Moro; Sergio Pedrazzoli
Journal:  J Gastrointest Cancer       Date:  2011-12

7.  Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade.

Authors:  Danielle M Bello; Katherine S Panageas; Travis Hollmann; Alexander N Shoushtari; Parisa Momtaz; Paul B Chapman; Michael A Postow; Margaret K Callahan; Jedd D Wolchok; Mary S Brady; Daniel G Coit; Charlotte E Ariyan
Journal:  Ann Surg Oncol       Date:  2019-12-17       Impact factor: 5.344

8.  Adrenalectomy for Metastatic Melanoma: Current Role in the Age of Nonsurgical Treatments.

Authors:  Devin C Flaherty; Gary B Deutsch; Daniel D Kirchoff; Jihey Lee; Kelly T Huynh; David Y Lee; Leland J Foshag; Anton J Bilchik; Mark B Faries
Journal:  Am Surg       Date:  2015-10       Impact factor: 0.688

9.  A prospective analysis of positron emission tomography and conventional imaging for detection of stage IV metastatic melanoma in patients undergoing metastasectomy.

Authors:  Steven E Finkelstein; Jorge A Carrasquillo; John M Hoffman; Barbara Galen; Peter Choyke; Donald E White; Steven A Rosenberg; Richard M Sherry
Journal:  Ann Surg Oncol       Date:  2004-07-12       Impact factor: 5.344

10.  MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome.

Authors:  J C Hassel; A Sucker; L Edler; H Kurzen; I Moll; C Stresemann; K Spieth; C Mauch; K Rass; R Dummer; D Schadendorf
Journal:  Br J Cancer       Date:  2010-08-24       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.